GlassScriptPhysician profile
Javed Shinwari
NPI 1184620643
$3,141.48
in general payments reported to CMS, 2019-2025
41 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $486 · 2022: $188 · 2023: $539 · 2024: $436 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Consulting Fee: $650 · Education: $77.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.10 |
| Consulting Fee | $650.00 |
| Education | $77.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $756.42 | 2023-2025 | Vanflyta, Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $455.00 | 2020 | |
| Myriad Genetic Laboratories, INC. | $238.00 | 2023 | Precisetumor |
| Novartis Pharmaceuticals Corporation | $153.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $125.88 | 2022-2025 | Welireg, Keytruda |
| Sirtex Medical INC | $110.55 | 2019 | |
| Kite Pharma, INC. | $105.13 | 2019 | |
| Menarini Silicon Biosystems, INC. | $91.84 | 2023 | Cellsearch |
| Tg Therapeutics, INC. | $90.14 | 2022 | |
| Abbvie INC. | $73.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.71 | 2022-2025 | Krazati, Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $65.90 | 2019-2025 | Fruzaqla, Iclusig |
| Genentech USA, INC. | $62.31 | 2024-2025 | Venclexta, Lunsumio, Polivy |
| Rigel Pharmaceuticals, INC. | $59.17 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $55.73 | 2024-2025 | Libtayo, Lynozyfic |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Shinwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.